Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: A comparative meta-analysis

Future Oncology

Volumn 11, Issue 7, 2015, Pages 1109-1122

  Abdel Rahman, Omar ^a   Elhalawani, Hesham ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

afatinib; erlotinib; gefitinib; interstitial lung disease; NSCLC

Indexed keywords

AFATINIB; DACOMITINIB; ERLOTINIB; GEFITINIB; ICOTINIB; PLACEBO; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG DOSE REDUCTION; DRUG FATALITY; HEMOPTYSIS; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG EMBOLISM; META ANALYSIS; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; COMPARATIVE STUDY; LUNG NEOPLASMS;

CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK;

EID: 84925831708     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.16     Document Type: Review

References (64)

1. GLOBOCAN. www.globocan.iarc.fr
2. Blais N, Hirsh V. Chemotherapy in metastatic NSCLC-new regimens (pemetrexed, nab-paclitaxel). Front. Oncol. 4, 177 (2014).
3. Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Design Dev. Ther. 8, 1037 (2014).
4. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167 (2000).
5. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 284, 31-53 (2003).
6. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat. Rev. 39(8), 839-850 (2013).
7. Roskoski R Jr. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol. Res. 87, 42-59 (2014).
8. Johnson JR, Cohen M, Sridhara R et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin. Cancer Res. 11(18), 6414-6421 (2005).
9. Moore, MJ, Goldstein, D, Hamm, J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J. Clin. Oncol. 23(16S), 1 (2005).
10. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin. Lung Cancer 10(2), 106-111 (2009).
11. Abdel-Rahman O, Fouad M. Risk of selected gastrointestinal toxicities in patients with advanced non small cell lung cancer receiving erlotinib; a systematic review and meta-analysis. Expert Rev. Anticancer Ther. doi:10.1 586/14737140.2015.1014035 (2015) (Epub ahead of print).
12. Pérez-Soler R, Chachoua A, Hammond, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
13. Liu V, White DA, Zakowski MF et al. Pulmonary toxicity associated with erlotinib. Chest J. 132(3), 1042-1044 (2007).
14. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: A review. Target. Oncol. 6(4), 235-243 (2011).
15. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364(10), 947-955 (2011).
16. Makris D, Scherpereel A, Copin MC et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7(1), 150 (2007).
17. Camus P, Foucher P, Bonniaud P, Ask K. Drug-induced infiltrative lung disease. Eur. Resp. J. 18(Suppl. 32), 93s-100s (2001).
18. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br. J. Cancer 91, S18-S23. (2004).
19. Cleverley JR, Screaton NJ, Hiorns MP, Flint JDA, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin. Radiol. 57, 292-299 (2002).
20. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am. J. Roentgenol. 175, 1019-1024 (2000).
21. Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin. Roentgenol. 37, 72-81 (2002).
22. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J. Clin. Epidemiol. 62(10), 1006-1012 (2009).
23. Johnson BE, Kabbinavar F, Fehrenbacher L et al. ATLAS: randomized, double-blind, placebo-controlled, Phase Iiib trial comparing bevacuzimab therapy with or without erlotinib, after completion of chemotherapy, with bevacuzimab for first-line treatment of advanced non-small-cell-lung cancer. J. Clin. Oncol. 31, 3926-3934 (2013).
24. Lee SM, Khan I, Upadhyay S et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 13, 1161-1170 (2012).
25. Pérol M, Chouaid C, Pérol D et al. Randomized, Phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 30, 3516-3524 (2012).
26. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
27. Stinchcombe TE, Peterman AH, Lee CB et al. A randomized Phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ?70 years) with stage IIIB/IV non-small cell lung cancer. J. Thorac. Oncol. 6(9), 1569-1577 (2011).
28. Natale RB, Thongprasert S, Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 1059-1066 (2011).
29. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol. 11(6), 521-529 (2010).
30. Mok, TS, Wu, YL, Thongprasert, S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
31. Lilenbaum R, Axelrod R, Thomas S et al. Randomized Phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J. Clin. Oncol. 26, 863-869 (2008).
32. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
33. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
34. Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
35. Ramalingam SS, Blackhall F, Krzakowski M et al. Randomized Phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 30, 3337-3344 (2012).
36. Goss GD, O'Callaghan C, Lorimer I et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 Study. J. Clin. Oncol. 31, 3320-3326 (2013).
37. Shi Y, Zhang L, Liu X et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind Phase 3 non-inferiority trial. Lancet Oncol. 14, 953-961 (2013).
38. Sun JM, Lee KH, Kim SW et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): An open-label, Phase 3 trial. Cancer 118(24), 6234-6242 (2012).
39. Ahn MJ, Yangb JCH, Liang J et al. Randomized Phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in east Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer 77, 346-352 (2012).
40. Zhang L, Ma S, Song X et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)-a multicentre, double-blind randomised Phase 3 trial. Lancet Oncol. 13, 466475 (2012).
41. Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 30(10), 1122-1128 (2012).
42. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
43. Lee DH, Park K, Kim JH et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin. Cancer Res. 16(4), 1307-1314 (2010).
44. Takeda K, Hida T, Sato T et al. Randomized Phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J. Clin. Oncol. 28(5), 753-760 (2010).
45. Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 27(30), 5080-5087 (2009).
46. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised Phase III trial. Lancet 372, 1809-1818 (2008).
47. Crinò L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, Phase II study. J. Clin. Oncol. 26(26), 4253-4260 (2008).
48. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26(26), 4244-4252 (2008).
49. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26(15), 2450-2456 (2008).
50. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537.
51. Sequist LV, Yang JCH, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
52. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised Phase 3 trial. Lancet Oncol. 15(2), 213-222 (2014).
53. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A Phase 2b/3 randomised trial. Lancet Oncol. 13(5), 528-538 (2012).
54. National cancer institute, common toxicity criteria. http://ctep.cancer.gov
55. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003).
56. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials 7(3), 177-188 (1986).
57. Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol. 27(15), 2523-2529 (2009).
58. Erlotinib prescribing information. www.gene.com
59. Gefitinib prescribing information. http://hemonc.org
60. Lai YC, Lin PC, Lai JI et al. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: A case report and literature review. Int. J. Clin. Pharmacol. Ther. 49(7), 461-466 (2011)
61. Hotta K, Kiura K, Takigawa N et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience. J. Thorac. Oncol. 5(2), 179-184 (2010).
62. Chang SC, Chang CY, Chen CY, Yu CJ. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J. Thorac. Oncol. 5(7), 1105-1106 (2010).
63. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer 83(2), 231-239 (2014).
64. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: A meta-analysis of 24 Phase III clinical trials. J. Chemother. 27(1), 40-51 2014).